Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gamida Cell Ltd
(NQ:
GMDA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gamida Cell Ltd
< Previous
1
2
3
4
Next >
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
September 28, 2022
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
Via
Benzinga
Recap: Gamida Cell Q2 Earnings
August 15, 2022
Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 01, 2022
Via
Benzinga
FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review
August 01, 2022
The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application (BLA) for omidubicel in the treatment of patients with blood cancers...
Via
Benzinga
Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients
April 27, 2022
Via
Benzinga
Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings
April 26, 2022
Via
Benzinga
Gamida Cell: Q4 Earnings Insights
March 15, 2022
Gamida Cell (NASDAQ:GMDA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Earnings Scheduled For August 15, 2022
August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Via
Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
August 12, 2022
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Via
Benzinga
Cell Therapy-Focused Gamida Plans To Cut 10% Of Staff
January 31, 2022
Gamida Cell Ltd (NASDAQ: GMDA) will terminat
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 25, 2022
On Monday, 100 companies reached new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
July 22, 2022
During Friday's session, 61 companies made new 52-week lows.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 16, 2022
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning.
Via
InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
June 16, 2022
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Gamida Cell: Q1 Earnings Insights
May 10, 2022
Gamida Cell (NASDAQ:GMDA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Gamida Cell reported in-line EPS of...
Via
Benzinga
Earnings Preview: Gamida Cell
May 09, 2022
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Gamida Cell will...
Via
Benzinga
The Daily Biotech Pulse - Tuesday, April,26
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For March 15, 2022
March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi...
Via
Benzinga
Preview: Gamida Cell's Earnings
March 14, 2022
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
Merck (MRK) Outperforms Industry, What's In Store For 2022?
March 07, 2022
Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.
Via
Talk Markets
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
Gamida Cell Shares Surge On Rolling Omidubicel Marketing Application In US
February 09, 2022
Gamida Cell Ltd (NASDAQ: GMDA) has initiated the Biologics License Application (BLA)
Via
Benzinga
48 Biggest Movers From Yesterday
January 21, 2022
Gainers Aptorum Group Limited (NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company announced it received FDA Orphan Drug designation for...
Via
Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
January 20, 2022
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 29.8% to $0.2550. Baudax Bio, last month, announced a $4.2 million registered direct offering. Vertical Aerospace Ltd. (NYSE...
Via
Benzinga
Hot Penny Stocks: What’s Moving VVOS, GMDA and SBEV Higher Today?
January 19, 2022
Several penny stocks are on the move Wednesday and we're diving into the hot news behind that momentum with a quick dive into the space.
Via
InvestorPlace
35 Stocks Moving In Wednesday's Mid-Day Session
January 19, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares jumped 67.1% to $26.15 after the company announced it will be acquired by UCB for approximately $1.9 billion. Splash Beverage Group,...
Via
Benzinga
52 Biggest Movers From Yesterday
January 20, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion. G...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.